novo nordisk glp-1 receptor agonist medications promotes new to fight diabetes, obesity < Pharma < Article Ozempic maker Novo Nordisk is
Description
The risk of depression associated with GLP-1RAs remains inconclusive, as studies have reported both an increased and decreased risk [18, 19]
Among those people, about 10% are severely obese, meaning they have BMIs of 40 or greater
News-Medical.net
doi: 10.1016/bs.pbr.2019.10.008
The GLP-1RA group reported lower subjective feelings of intoxication during the early timepoints of the session, as indicated by reduced ratings on the Visual Analog Scale (VAS) for How drunk do you feel?
Nogueira, J
